2026-06-28T20:40:26Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1141212025-01-15T00:48:00Zcom_20.500.14352_14col_20.500.14352_15

Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation Fernández Vázquez, María Inmaculada Meneu Díaz, Juan Carlos Colina Ruiz-Delgado, Francisco García, Ignacio Muñoz Gómez, Raquel Castellano Tortajada, Gregorio Fuertes, Antonio Abradelo De Usera, Manuel Lumbreras Bermejo, Carlos Juan Moreno González, Enrique Solís Herruzo, José Antonio Treatment of recurrent hepatitis C in liver transplant is controversial. The aim of our study was to evaluate the clinical and histological efficacy of pegylated interferon alpha 2b (PEG-IFN) and ribavirin therapy of recurrent hepatitis C after liver transplantation (LT). We prospectively included 47 liver transplant patients with: 1) a positive test for hepatitis C virus (HCV)-ribonucleic acid (RNA) in serum; 2) alanine aminotransferase (ALT) >45 UI/mL; and 3) a liver biopsy showing chronic hepatitis without rejection in the previous 2 months. Patients received PEG-IFN (1.5 μg/kg/week) and ribavirin (800-1,000 mg/day) for 12 months. Follow-up was based on biochemical (ALT), virological (RNA-HCV), and histological (liver biopsy) examinations. Follow-up lasted a minimum of 6 months after the end of antiviral therapy. Sustained virological response (SVR) was achieved in 23% of the patients. A total of 33 (70%) patients had normalized ALT levels at the end of therapy. Inflammatory portal and lobular score declined significantly in patients with SVR (P < 0.05) but not in nonresponder patients. Fibrosis did not change significantly in either group. SVR was significantly associated with low γ-glutamyltransferase GGT (P = 0.04) and HCV-RNA levels (P = 0.03), a virological response at 12 weeks (P = 0.002) and patient's compliance (P = 0.04). Ten (21%) patients were withdrawn prematurely due to adverse effects. In conclusion, Therapy with PEG-IFN and ribavirin achieved SVR and a significant histological improvement in 23% of liver transplant recipients with chronic hepatitis C. Toxicity is an important drawback of this therapy. Liver Transpl 12:1805-1812, 2006. © 2006 AASLD. 2025-01-14T08:34:02Z 2025-01-14T08:34:02Z 2006 journal article Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl. 2006 Dec;12(12):1805-12. doi: 10.1002/lt.20883. 1527-6465 10.1002/lt.20883 https://hdl.handle.net/20.500.14352/114121 1527-6473 https://doi.org/10.1002/lt.20883 17133585 https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/lt.20883 https://pubmed.ncbi.nlm.nih.gov/17133585/ eng restricted access Wiley